← Eichor
Study identifier: NCT05879653 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

Condition: Bladder Cancer  ·  Sponsor: Kyoto University Hospital

PhasePhase 2
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is designed to assess the efficacy and safety of induction therapy with MK-3475 and ASG-22CE and radiation therapy with MK-3475 in patients with cT2-4aN0M0 muscle invasive bladder cancer who are unfit for or refuse radical cystectomy.

This description comes directly from the study's public registry record.

Talk to the study team

Yuki Kita, MD,PhD  ·  81757513337  ·  kitayuki@kuhp.kyoto-u.ac.jp

Always discuss trial participation with your own doctor first.

Locations (4)

Kobe City Medical Center General HospitalKobe, Hyōgo, JapanRecruiting
University of Tsukuba HospitalTsukuba, Ibaraki, JapanRecruiting
Kyoto University HospitalKyoto, Kyoto, JapanRecruiting
Osaka Metropolitan University HospitalOsaka, Osaka, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05879653